Experimental combo targets Tough-to-Treat leukemia
NCT ID NCT02787369
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new drug called ACY-1215 (ricolinostat) combined with either ibrutinib or idelalisib in people whose chronic lymphocytic leukemia has returned after prior treatment. The main goal is to find a safe dose, while also checking if the combination helps shrink cancer or delay its growth. Only 3 participants were enrolled, so results are very preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ricolinostat (ACY-1215) combined with ibrutinib or idelalisib
What this could lead to
If successful, this could point toward a new combination treatment option for patients with relapsed chronic lymphocytic leukemia.
What could go wrong
This is a very early, small Phase 1 trial with only 3 participants, so results may not apply broadly. The combination may cause unexpected side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT CHRONIC LYMPHOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States